Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2015

01-02-2015 | Melanomas

In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

Authors: Georgia Beasley, Douglas Tyler

Published in: Annals of Surgical Oncology | Issue 2/2015

Login to get access

Excerpt

In this issue of Annals of Surgical Oncology, Read and colleagues describe a cohort analysis of the incidence, prognosis, and role of lymphadenectomy for in-transit (IT) melanoma. The study contributes to the large volume of clinical research this group has contributed to IT melanoma specifically and melanoma in general. The data they describe from a large prospectively maintained melanoma database can help clinicians understand this unusual presentation of stage 3 disease and also can be used to optimize treatment strategies for this patient population. …
Literature
1.
go back to reference Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–96. Epub 16 January 2005.PubMedCrossRef Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–96. Epub 16 January 2005.PubMedCrossRef
2.
go back to reference Beasley GM, Speicher PJ, Sharma K, Jiang B, Salama AKS, Seigler H, Mosca PJ, Tyler DS. Efficacy of repeat sentinel lymph node biopsy for patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686–92. Epub 24 December 2013.PubMedCrossRef Beasley GM, Speicher PJ, Sharma K, Jiang B, Salama AKS, Seigler H, Mosca PJ, Tyler DS. Efficacy of repeat sentinel lymph node biopsy for patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686–92. Epub 24 December 2013.PubMedCrossRef
3.
go back to reference Ariyan CE, Brady MS. History of regional chemotherapy for cancer of the extremities (review). Int J Hypertherm. 2008;24:185–92.CrossRef Ariyan CE, Brady MS. History of regional chemotherapy for cancer of the extremities (review). Int J Hypertherm. 2008;24:185–92.CrossRef
4.
go back to reference Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Petersen B, Seigler H, Pruitt SK, Tyler DS. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306–16. Epub 13 April 2011.PubMedCentralPubMedCrossRef Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Petersen B, Seigler H, Pruitt SK, Tyler DS. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306–16. Epub 13 April 2011.PubMedCentralPubMedCrossRef
5.
go back to reference Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol. 2014. doi:10.1245/s10434-014-3979-9. Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol. 2014. doi:10.​1245/​s10434-014-3979-9.
6.
go back to reference Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.PubMedCentralPubMedCrossRef Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.PubMedCentralPubMedCrossRef
7.
go back to reference Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
8.
go back to reference Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S. Intralesional injection of Rose Bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2013;8:e68561.PubMedCentralPubMedCrossRef Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S. Intralesional injection of Rose Bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2013;8:e68561.PubMedCentralPubMedCrossRef
9.
go back to reference Jiang BS, Beasley GM, Speicher PJ, Mosca PJ, Morse MA, Hanks B, Salama A, Tyler DS. Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. Ann Surg Oncol. 2014;21:2525–31.PubMedCrossRef Jiang BS, Beasley GM, Speicher PJ, Mosca PJ, Morse MA, Hanks B, Salama A, Tyler DS. Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. Ann Surg Oncol. 2014;21:2525–31.PubMedCrossRef
10.
go back to reference Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma (review). J Surg Oncol. 2014;109:314–9. doi: 10.1002/jso.23554. Epub 10 February 2014. Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma (review). J Surg Oncol. 2014;109:314–9. doi: 10.1002/jso.23554. Epub 10 February 2014.
11.
go back to reference Olofsson R, Lindberg E, Karlsson-Parra A, Lindnér P, Mattsson J, Andersson B. Melan-A specific CD8 + T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hypertherm. 2013;29:234–8.CrossRef Olofsson R, Lindberg E, Karlsson-Parra A, Lindnér P, Mattsson J, Andersson B. Melan-A specific CD8 + T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hypertherm. 2013;29:234–8.CrossRef
Metadata
Title
In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
Authors
Georgia Beasley
Douglas Tyler
Publication date
01-02-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4110-y

Other articles of this Issue 2/2015

Annals of Surgical Oncology 2/2015 Go to the issue